Vijay K. Iyengar M.D.
Net Worth

Last updated:

What is Vijay K. Iyengar M.D. net worth?

The estimated net worth of Dr. Vijay K. Iyengar M.D. is at least $15,216,934 as of 29 Nov 2024. He owns shares worth $2,620,033 as insider, has earned $5,975,601 from insider trading and has received compensation worth at least $6,621,300 in Incyte Corporation.

What is the salary of Vijay K. Iyengar M.D.?

Dr. Vijay K. Iyengar M.D. salary is $945,900 per year as Executive Vice President of Global Strategy & Corporation Devel. in Incyte Corporation.

How old is Vijay K. Iyengar M.D.?

Dr. Vijay K. Iyengar M.D. is 52 years old, born in 1973.

What stocks does Vijay K. Iyengar M.D. currently own?

As insider, Dr. Vijay K. Iyengar M.D. owns shares in one company:

Company Title Shares Price per share Total value
Incyte Corporation (INCY) Executive Vice President of Global Strategy & Corporation Devel. 30,658 $85.46 $2,620,033

What does Incyte Corporation do?

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Vijay K. Iyengar M.D. insider trading

Incyte Corporation

Dr. Vijay K. Iyengar M.D. has made 19 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently he sold 5,683 units of INCY stock worth $428,328 on 29 Nov 2024.

The largest trade he's ever made was exercising 15,571 units of INCY stock on 25 Jul 2024. As of 29 Nov 2024 he still owns at least 30,658 units of INCY stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 5,683 $75.37 $428,328
Sale
Common Stock 360 $75.6 $27,216
Sale
Common Stock 15,571 $70 $1,089,970
Sale
Common Stock 657 $65 $42,705
Option
Common Stock 7,000 $68.62 $480,340
Option
Non-Qualified Stock Option (right to buy) 7,000 $68.62 $480,340
Sale
Common Stock 7,000 $85 $595,000
Sale
Common Stock 804 $80.77 $64,939
Sale
Common Stock 1,654 $80.79 $133,627
Option
Common Stock 7,000 $68.62 $480,340
Option
Common Stock 7,866 $72.86 $573,117
Option
Non-Qualified Stock Option (right to buy) 7,000 $68.62 $480,340
Sale
Common Stock 7,000 $80.8 $565,600
Sale
Common Stock 5,787 $79.38 $459,372
Sale
Common Stock 4,911 $78.29 $384,482
Option
Incentive Stock Option (right to buy) 4,116 N/A N/A
Option
Common Stock 4,116 N/A N/A
Sale
Common Stock 5,116 N/A N/A
Sale
Common Stock 475 $108.56 $51,566
Sale
Common Stock 3,120 $107.98 $336,898
Option
Non-Qualified Stock Option (right to buy) 7,866 $72.86 $573,117
Option
Common Stock 7,866 $72.86 $573,117
Sale
Common Stock 7,866 $72.86 $573,117
Sale
Common Stock 7,366 $95 $699,770
Option
Non-Qualified Stock Option (right to buy) 7,366 $95 $699,770
Option
Common Stock 7,366 $95 $699,770
Sale
Common Stock 500 $72.86 $36,430
Option
Non-Qualified Stock Option (right to buy) 500 $72.86 $36,430
Option
Common Stock 500 $72.86 $36,430
Sale
Common Stock 930 $85 $79,050
Sale
Common Stock 606 $71.34 $43,232
Option
Common Stock 5,000 $72.86 $364,300
Sale
Common Stock 5,000 $72.86 $364,300
Option
Non-Qualified Stock Option (right to buy) 5,000 $72.86 $364,300

Incyte key executives

Incyte Corporation executives and other stock owners filed with the SEC: